

UNIQUE IDENTIFIER NO: C-67-2013  
EQUIP-2017-074  
Review Date: July 2020  
Review Lead: Lead Infection Prevention & Control Nurse

## **Section S - Tuberculosis Policy**

### **Version 7**

**Important:** This document can only be considered valid when viewed on the Trust's Intranet. If this document has been printed or saved to another location, you must check that the version number on your copy matches that of the document online.

UNIQUE IDENTIFIER NO: C-67-2013

EQUIP-2017-074

Review Date: July 2020

Review Lead: Lead Infection Prevention & Control Nurse

Document Summary Table		
Reference Number	C-67-2013	
Status	Ratified	
Version	7	
Implementation Date	January 2003	
Current/Last Review Dates	November 2008, May 2013, June 2015, July 2017	
Next Formal Review	July 2020	
Sponsor	Director of Infection Prevention & Control	
Author	Senior Infection Prevention & Control Nurse	
Where available	Trust Intranet	
Target audience	All Staff	
Ratifying Committee		
Executive Board	31 August 2017	
Consultation Committee		
Committee Name	Committee Chair	Date
Infection Prevention & Control Committee	Consultant Microbiologist / Infection Prevention & Control Doctor	July 2017
Other Stakeholders Consulted		
All members of Infection Prevention and Control Committee	July 2017	
Respiratory Consultants and TB Team	July 2017	

Does this document map to other Regulator requirements?	
<i>Regulator details</i>	<i>Regulator standards/numbers etc</i>

Document Version Control	
Version No.	<i>Brief details of revisions or rationale of new Trust wide policy</i>
7	Revision of the content to include NICE 2016 guidance, revise references and inclusion of an IPC requirements chart.
6	Amendment Jan 2017, links updated.
5	Guidance on notifying TB cases has been included in Appendix 1. Links added to various documents in the References section. A link included in Section 17- information on notifiable diseases and the form. The PHE 'Guide for risk assessment of TB exposure incidents in hospitals' has been included in Appendix 4. The Standard Operating Procedure (Appendix 6) revised and amended.
4	The MDR-TB section has been revised and moved to the main body. NICE guidelines verified and the policy cross referenced with this. The Trust Equality Statement has been updated.
3	The document has been redesigned to the Trust format and core content. Monitoring arrangements for this document have been included.

**UNIQUE IDENTIFIER NO: C-67-2013**

**EQUIP-2017-074**

**Review Date: July 2020**

**Review Lead: Lead Infection Prevention & Control Nurse**

## **Contents**

<b>Section</b>		<b>Page</b>
	Document Summary Table	2
	Contents	3
1.	Introduction	4
	1.1 Key points	4
2.	Purpose	5
3.	Definitions	5
4.	Duties	6
5.	Management of TB in hospital	6
	5.1 Risk Assessment	6
	5.2 Diagnosis – sample taking	7
	5.3 Prevention of transmission	8
	5.4 Isolation of patients	9
	5.5 DOL	10
	5.6 Termination of Isolation	10
	5.7 Visitors	11
	5.8 PPE including use of masks	11
	5.9 Respiratory hygiene / cough etiquette	12
	5.10 Operating Theatres & Respiratory	12
	5.11 Discharge or transfer of known or suspected TB	13
	5.12 Death of a patient with TB	13
6.	Notification	13
7.	Staff screening / Immunity	14
8.	Management of Outbreaks & Incidents	15
9.	TB Management Contacts	16
10.	Training and Implementation	17
11.	Trust Equalities Statement	17
12.	Process for Monitoring Compliance / Effectiveness	17
13.	References and Further Reading	17
<b>Appendices</b>		
1.	Guidance on notifying Tuberculosis cases	19
2.	Location of Negative Pressure Rooms at CRH	20
3.	Assessment of Isolation Requirements	22
4.	PHE Guidance for risk assessment – TB exposure incidents in hospital	25
5.	Contact Tracing	27
6.	Patients who have come into contact with Index Case	29
	Standard Operating Procedure for Contact Tracing for the IPCT	

**UNIQUE IDENTIFIER NO: C-67-2013**

**EQUIP-2017-074**

**Review Date: July 2020**

**Review Lead: Lead Infection Prevention & Control Nurse**

## **1. Introduction**

Tuberculosis (TB) is a bacterial infection spread through the inhalation of the microorganism expelled from the mouth and nose of an infectious individual after close and prolonged exposure by coughing, sneezing and talking. It is caused by organisms belonging to the *Mycobacterium tuberculosis* complex, which includes: *Mycobacterium tuberculosis*, *Mycobacterium africanum*, and *Mycobacterium bovis*. Other Mycobacterial species other than those in the *Mycobacterium tuberculosis* complex are commonly referred to as “atypical” mycobacteria. They do not pose the same infection risk as TB.

TB usually affects the lungs, but can affect other parts of the body including lymph nodes, bones and brain. It develops slowly and it may take several months for symptoms to appear. The most common symptoms include:

- Shortness of breath
- Cough
- Unexplained loss of weight
- Loss of appetite
- Fever and night sweats
- Fatigue

### **1.1 Key points summary**

- TB is a notifiable disease and suspected and confirmed cases must be notified to Public Health England (see Appendix 1).
- Patient with confirmed or suspected MDR-TB **must** be isolated in a negative pressure room.
- Not all cases of TB require isolation, only those considered infectious or with multi-drug resistant TB – take advice from the TB team about the infection status of a known case of TB.
- Key TB team contacts (office hours only) are:
  - Calderdale (CHFT) – 01422 307330/ 07824 343770/ 07795 825 070
  - Kirklees (Locala) – 07773 202567
  - Dewsbury– 0303 3309869
- FFP3 Masks are always needed to protect staff from MDR-TB. These must be fit tested to ensure the mask is suitable for the wearer (in advance of need) and fit checked at each use.
- Do not de-escalate a TB patient’s isolation without consulting the IPC team, microbiologist and Lead TB Consultant

UNIQUE IDENTIFIER NO: C-67-2013

EQUIP-2017-074

Review Date: July 2020

Review Lead: Lead Infection Prevention & Control Nurse

## 2. Purpose

The purpose of this policy is to ensure that suspected or confirmed TB cases are managed in line with best practice and the risks of cross infection to patients, staff and others are minimised.

## 3. Definitions

- **Acid Fast Bacilli (AFB)** – mycobacteria are shaped like rods and can be seen under the microscope. Staining mycobacteria with dye and washing them with acid can help identify TB because the rods will remain stained – AFB positive.
- **Contact tracing** - this identifies contacts of the TB case and checks for anyone who has symptoms of TB, tests for those with latent TB infection (see below) and identifies those who would benefit from BCG vaccination.
- **Extensively drug resistant TB (XDR TB)** MDR TB and resistant to any fluoroquinolone and at least one of three injectable second- line drugs (*i.e* amikacin, kanamycin or capreomycin).
- **Latent TB infection (LTBI)** - is when a person has the bacteria that cause TB in their body but it is not causing disease *i.e.* the bacteria are dormant. It is possible that the bacteria may cause disease in the future.
- **Multi- drug resistant TB (MDR- TB)** - *M tuberculosis* resistant to isoniazid and rifampicin; with or without resistance to other anti-TB drugs.
- **Pulmonary tuberculosis** - a case of TB involving the lungs (including laryngeal TB).
- **Negative pressure isolation rooms** - used for patients with an airborne transmitted infection. Airflow is pulled from the corridor into the patient's room and is vented to the outside.
- **Respiratory Isolation** - is a set of measures to prevent the spread of an airborne infection. This includes isolation and, if applicable, the use of masks.

## 4. Duties

As a registered healthcare provider, CHFT has a duty to comply with the Health & Safety Act (1974), (HSE 2003), COSHH (HSE 2005) and the Health and Social

**UNIQUE IDENTIFIER NO: C-67-2013**

**EQUIP-2017-074**

**Review Date: July 2020**

**Review Lead: Lead Infection Prevention & Control Nurse**

Care Act (DH 2008) code of practice on the prevention and control of infections and related guidance.

The Chief Executive is responsible for ensuring that there are effective infection control arrangements in the Trust.

The Lead TB Consultant is responsible for the clinical management of adult TB cases.

The TB teams support individuals affected by TB in line with NICE guidelines and Standard Operating Procedures

### **Consultation and Communication with Stakeholders**

The Infection Prevention & Control Committee (IPCC), TB Clinical Leads and the Infection Prevention & Control Team (IPCT) comment on and contributed to this policy. The policy is ratified at the IPCC and approved by the Executive Board (EB).

## **5. Management of TB in hospital**

Most **confirmed** TB patients are managed as outpatients, supported by the TB Team, and are generally **no longer infectious following 2 weeks of effective treatment**. However, it may be necessary for a patient to be admitted to hospital while they are infectious, either due to their TB infection or for another reasons.

Where TB is **suspected** or is considered a **differential diagnosis**, the patient will need to be managed as a TB case until laboratory tests or alternate diagnosis rules out TB.

### **5.1 Risk assessment – is the patient infectious?**

Risk assessment identifies the risk associated with the patients TB infection and therefore what measures need to be taken to prevent transmission within the hospital.

Initial assessment should be completed without delay to assess for the risk of multi-drug resistance (MDR or XDR). If this risk assessment cannot be done expeditiously, then MDR-TB precautions should be applied until confirmed otherwise:

1. History of prior TB drug treatment; prior TB treatment failure
2. Contact with a known case of drug-resistant TB
3. Birth in a foreign country, particularly high-incidence countries as defined by Public Health England on its [website](#): \*High incidence rate is estimated incidence rate of 40 per 100,000 or greater.

**UNIQUE IDENTIFIER NO: C-67-2013**

**EQUIP-2017-074**

**Review Date: July 2020**

**Review Lead: Lead Infection Prevention & Control Nurse**

4. HIV infection
  5. Residence in London
- A. **MDR-tuberculosis** if any of the above circumstances are known to apply at, or discovered after, the time of patient admission. **NOTE: any patient co-infected with MDR-TB and HIV MUST be transferred to LEEDS.**

Patients **without** any identified risk factors for drug resistance will fall into the following categories.

- B. **Clinically and/or radiologically suspected pulmonary TB** but sputum smear results awaited (on the basis of three samples – see below).
- C. **Sputum or bronchoscopy smear (AFB) positive tuberculosis** on the basis of one or more samples. These patients should be considered **significantly** infectious. Any sputum smear positive (AFB) should be assumed to be *M. tuberculosis* until confirmed otherwise.
- D. **Smear negative sputum status** is on the basis of three sputum samples collected at least 8 hours apart, with at least one being an early morning sample. Each sputum sample should be at least 5 mls, and obtained from a deep productive cough (saliva and naso-pharyngeal secretions are not sputum). Patients who are sputum smear negative normally present a reduced risk of infection to others in hospital. Such patients **may** be managed on a standard ward following standard IP&C precautions, but only if there are no immunocompromised patients present and there is no risk of MDR TB. This should be discussed and agreed with the IP&C Team.
- E. Non-respiratory tuberculosis is not infectious to others, but may require isolation for some procedures

## **5.2 Diagnosis - sample taking**

- Three sputum samples collected at least 8 hours apart, with at least one being an early morning sample.
- Sputum sample should be at least 5 mls, and obtained from a deep productive cough (saliva and naso-pharyngeal secretions are not sputum).
- Sputum and bronchoalveolar lavage (BAL) specimens from known or suspected TB patients should be labelled **INFECTION RISK** and **SHOULD NOT UNDER ANY CIRCUMSTANCES BE TRANSPORTED BY ANY AIR TUBE SYSTEM.**

**UNIQUE IDENTIFIER NO: C-67-2013**

**EQUIP-2017-074**

**Review Date: July 2020**

**Review Lead: Lead Infection Prevention & Control Nurse**

\* Where MDR-TB is suspected, rapid nucleic acid amplification tests for rifampicin resistance on primary specimens should be requested.

### 5.3 Prevention of transmission

The following section summarises the IPC measures for each of the categories above and describes each element in more detail.

		A – MDR TB confirmed or suspected	B – suspected pulmonary TB not MDR	C – Smear positive	D – smear negative	E – non-pulmonary
ISOLATION	Isolation room – negative pressure	✓		✓		
	Standard Isolation room		✓		IPC	IPC
MASKS	Mask FFP3 – staff entering room and until leaving the room	✓				
	Mask FFP3 - staff performing aerosolising procedures*	✓	✓	✓	IPC	IPC
	Mask Surgical - patient on transfer between depts	✓	✓	✓		
	Mask FFP3 – for visitors	✓				
	Visitors – assess for TB prior to visiting	✓	✓	✓		
	Visitors – restricted to close contacts	✓	✓	✓		
	Infection site waste managed as infectious (e.g. sputum, wound etc)	✓	✓	✓	✓	✓

IPC = discuss options with IPC

\* e.g bronchoscopy, chest physiotherapy, sputum induction, intubation.

### 5.4 Isolation of patients with confirmed or suspected TB

**UNIQUE IDENTIFIER NO: C-67-2013**

**EQUIP-2017-074**

**Review Date: July 2020**

**Review Lead: Lead Infection Prevention & Control Nurse**

When in hospital, patients in categories A, B or C, including those initially sputum smear negative but sputum smear positive after bronchoscopy, must be admitted directly into an isolation room. **For MDR-TB this must be the first available negative pressure room preferably on a respiratory ward. For suspected TB this should be into a side room. For a smear positive TB this should be a negative pressure room** (see Appendix 2 for locations).

Isolation must be continued until the patient is declared non-infectious by the Consultant microbiologist and TB Consultant or is discharged.

- All staff are required to follow CHFT Isolation policy (Section K) when caring for patients within isolation
- Staff contact should be kept to a reasonable minimum without compromising patient care
- The door must be closed **at all times** except for necessary access
- Patients in isolation should not visit communal or public areas of the ward or hospital, nor should they visit or pass through areas that may contain immunosuppressed patients
- All clinical waste should be disposed of via the infectious waste stream. A lidded orange waste bin is to be available outside the isolation room
- Where required, a supply of FFP3 masks must be available outside the isolation room
- When TB is confirmed or suspected (even if considered non-infectious), cough inducing procedures and production of sputum must **NEVER** be performed on the open ward or bay. They should be performed in the isolation room or a treatment room with the door closed
- Patients with MDR-TB take **absolute priority** in the allocation of the negative pressure rooms. In order for the negative pressure to work correctly the isolation room door, en-suite door and window must remain closed
  - Before the patient is admitted to the negative pressure room the ventilation and pressure record reading is to be documented in the patient's EPR record and advice given as to whether the room is suitable for use. This information can be obtained from Engie. Throughout the patient's stay, the negative pressure reading should be documented on a daily basis within the patient's notes

**UNIQUE IDENTIFIER NO: C-67-2013**

**EQUIP-2017-074**

**Review Date: July 2020**

**Review Lead: Lead Infection Prevention & Control Nurse**

- Out of hours / weekends the Site Coordinator or Duty Matron are able to arrange the switching of a side room to negative pressure room
- If it is necessary for the patient to go to Theatre, the Theatre pressure should be set to neutral

## **5.5 DOL (Deprivation of Liberty)**

Patients with inadequately controlled TB may pose a significant infection risk to others, especially if they are sputum smear positive, and noncompliant with prescribed oral therapy, or have MDR-TB. The isolation of such patients is paramount to protect other individuals. In **very occasional** circumstances a Court Order restricting a patient's location/movements may be required in the interests of the wider public health. Any individual CHFT patient case where such legal restrictions might be required should be discussed with Public Health England. The IPCT should also be informed.

## **5.6 Termination of Isolation**

The decision to terminate isolation is made by the supervising physician in collaboration with the Infection Prevention and Control Team and the Consultant Microbiologist only.

Uncomplicated (sensitive) pulmonary TB will become non-infectious after two weeks of compliant anti-TB therapy. The results of sputum cultures and the response to treatment will be taken into account.

In the circumstances outlined below, three negative sputum smear examinations on successive days must be confirmed before removing a patient from isolation:

- If the patient was particularly infectious (infection transmitted to more than 10% of close household and/or casual contacts).
- If MDR-TB is possible or confirmed
- If the patient is to be transferred to an open ward containing immunocompromised or HIV positive patients.

## **5.7 Visitors**

Visitors should be limited to those who have already been in close contact with the patient before diagnosis (such as persons living in the same house).

In addition:

**UNIQUE IDENTIFIER NO: C-67-2013**

**EQUIP-2017-074**

**Review Date: July 2020**

**Review Lead: Lead Infection Prevention & Control Nurse**

- **Visitors** of children should be isolated from other patients until they have been screened and pronounced non-infectious. One of the visitors may be the source of the child's TB and pose a significant infection risk to other patients on the ward.
- Children under two years of age should **not** visit unless the children have had significant contact with the patient and are being followed up as a "close contact".
- MDR-TB patient visitors who refuse to wear masks on the grounds that they have been, or may continue to be, exposed outside the hospital should not be prevented from visiting but such refusal should be documented.
- MDR-TB patient close contacts must be assessed by the TB team for possible active tuberculosis and declared non-infectious before being allowed to visit. Visitors who have yet to be assessed as above, and who have a persistent cough should be asked not to visit until declared clear as above.

## **5.8 Personal protective equipment including the use of Masks**

Standard Infection Prevention and Control Precautions (Infection Control Policies & Guidelines, Section C) must be maintained for all patients e.g. hand hygiene, single use gloves and aprons where appropriate.

**Masks** are used to protect staff from inhalation of TB mycobacteria or when worn by the patient with TB, to contain the infection if transit between hospital areas is required. The requirements depend upon the type of TB being managed.

- **FFP 3 Masks** are recommended for staff when:
  - Exposure to large numbers of *M. tuberculosis* bacilli is possible, e.g. bronchoscopy and aerosol generating procedures, including chest physiotherapy, sputum induction etc.
  - Prolonged (>8hrs/shift) high dependency care of a coughing TB patient
  - Entering the isolation room of an MDR TB patient

The patient should wear a surgical mask if they need to attend another department.

All clinical staff for in-patient areas should ensure they are 'fit tested' for an FFP 3 masks **prior to use**. Further information about fit testing can be found on the intranet.

If FFP 3 masks are urgently required, a very small stock is available in the Infection Prevention and Control Emergency Cupboard. **At the earliest opportunity the**

**UNIQUE IDENTIFIER NO: C-67-2013**

**EQUIP-2017-074**

**Review Date: July 2020**

**Review Lead: Lead Infection Prevention & Control Nurse**

**ward must ensure they have ordered and have an adequate supply of FFP3 masks.**

### **5.9 Respiratory hygiene/cough etiquette:**

Patients are to be advised on respiratory etiquette as part of their care.

- to use tissues to cover their mouth and nose when coughing/sneezing to contain respiratory secretions
- to dispose of tissues into an appropriate waste receptacle for them prior to discarding into an orange clinical waste bag
- to perform hand hygiene after contact with respiratory secretions and contaminated items

### **5.10 Operating Theatres & Respiratory / Invasive Intervention**

- Infectious TB patients (confirmed or suspected) should be placed last on the operating/scoping list. Consideration should be given as to whether the procedure can be deferred (especially if involving a general anaesthetic) until the patient is deemed “non-infectious”
- The operating theatre should be cleaned as normal following the list
- If patients with confirmed or suspected pulmonary TB require assisted ventilation in either ICU or theatre, the ventilator must be fitted with a bacterial filter
- If patients require suction via an endotracheal tube or tracheostomy a closed suction system must be used. All respiratory equipment (endotracheal tubes, ventilator circuits etc.) must be single use
- Bronchoscopes should be decontaminated according to local policy for TB

### **5.11 Discharge or transfer of known or suspected TB**

Consideration must be given to any infection risk the patient may pose on discharge. The discharge plan should be made in consultation with the TB team supporting the patient through treatment as well as those involved in the patients’ management in hospital.

**For cases of MDR-TB** a Consultant Microbiologist, Public Health England CCDC, and the IPCT should be involved in the decision.

**UNIQUE IDENTIFIER NO: C-67-2013**

**EQUIP-2017-074**

**Review Date: July 2020**

**Review Lead: Lead Infection Prevention & Control Nurse**

- The Inter healthcare Infection Control Transfer Form must be completed for all patients being permanently transferred to another area (IPC Policy for Bed Management and Movement of Patients section W)
- The isolation room requires a terminal clean and curtain change (amber) using a chlorine-based disinfectant (e.g. Tristel)

### **5.12 Death of a patient with TB**

If a patient with confirmed or suspected TB **of any type and from any body site** dies, the mortuary must be informed and the patient placed in a cadaver bag with **INFECTION RISK** stickers attached to the mortuary labels (Care of the Deceased Body, Section P).

For notification after death, please see Section B Notifiable Diseases Policy.

## **6. Notification**

All cases of confirmed or suspected TB infection are notifiable as described below, including following death (including post mortem diagnoses).

Notification is required for:

1. Culture confirmed case due to *M. tuberculosis* complex (including *M. tuberculosis*, *M. bovis*, *M. africanum* or *M. microti*).
  2. In the absence of culture confirmation, a case that meets the following criteria:  
a clinician's judgement that the patient's clinical and/or radiological signs and/or symptoms are compatible with tuberculosis,  
**AND**  
a clinician's decision to treat the patient with a full course of anti-TB therapy.
- Notification also applies to UK residents who are diagnosed abroad but continue with their anti-TB therapy in the UK and to non-UK residents diagnosed in the UK, even if anti-TB therapy is not initiated in the UK
  - Locally the Lead TB Consultant will notify all cases of TB started on treatment. Please see Appendix 1 for more detailed guidance on notifying TB cases
  - For sputum smear positive patients especially if they have been in contact with children or others at a high risk of acquiring TB, the **TB nurses should also be informed promptly**. This does NOT remove the need for statutory notification, but enables efficient case management and contact tracing

**UNIQUE IDENTIFIER NO: C-67-2013**

**EQUIP-2017-074**

**Review Date: July 2020**

**Review Lead: Lead Infection Prevention & Control Nurse**

- **MDR-TB additional notification requirements** - The IPCT, Lead TB Consultant and if appropriate the TB physician who specialises in MDR-TB at St. James University Hospital, Leeds, must be informed of the admission as soon as possible. In addition, the BTS MDRTB Forum are notified by the Lead TB Consultant
- If a staff member is suspected to have acquired TB during the course of their work at CHFT, this should be reported to the Health and Safety Executive as a disease identified under the Reporting of Injuries, Disease and Dangerous Occurrences Regulations (RIDDOR)

## **7. Staff Screening/Immunity**

Staff must comply with Occupational Health Service procedures for TB. In particular:

- Attending Occupational Health if they have been requested to do so: for example
- For TB screening/immunisation on commencement of employment
  - If they have been working clinically in countries with a high TB incidence (WHO definition >40 cases per hundred thousand)
  - If advised screening is required following exposure to an infectious TB case at work
  - If they have reason to believe they have been exposed to TB
- Staff who do not have evidence of protection/immunity are advised to avoid contact with known or suspected cases of TB
- Staff who have suppressed immunity **MUST** avoid contact with known or suspected cases of TB
- Managers should ensure that staff comply with the above requirements
- If unsure of their status, staff can refer themselves to CHFT Occupational Health Service

Any CHFT staff member who develops symptoms of TB are to seek medical advice from their GP and report to Occupational Health Services as soon as possible.

### **7.1 Staff contacts of a TB patient**

Most occupational contacts are considered to be casual contacts. Further examination is only necessary if:

**UNIQUE IDENTIFIER NO: C-67-2013**

**EQUIP-2017-074**

**Review Date: July 2020**

**Review Lead: Lead Infection Prevention & Control Nurse**

- The index case is smear positive and the contact is unusually susceptible, e.g. immunocompromised
- The index case is considered highly infectious as shown by transmission to more than 10% of close contacts

## **8.0 Management of Outbreaks & Incidents**

Where an infectious patient has been nursed with other patients in a ward area for more than 8 hours a risk assessment must be carried out. Public Health England (PHE) must be involved in the risk assessment process (Appendix 4).

The Infection Prevention & Control Doctor (IPCD) has overall responsibility for co-ordinating the management of an outbreak of TB or an incident involving TB. The IPCD will co-ordinate immediate action to:

- Prevent or reduce the risk of further cases
- Arrange collection and recording of microbiological and epidemiological information as required
- Convene an urgent Outbreak Control Team (OCT) meeting
- With support from the IPCT, the Ward Manager will collate a list of patient contacts
- Initial risk assessment would take place between an IPCN, the patient's clinical team and the CHFT Microbiologist. This list is then passed onto the TB team to contact patients
- The IPCT or TB Specialist Nurses will advise ward or work area manager to collate a list of staff potentially exposed to the patient with undiagnosed pulmonary tuberculosis. It is important the list includes all health care workers e.g physiotherapists. The list should include the nature of the exposure (e.g. during CPR) but does not need to include the susceptibility of individual health care workers
- Information about the signs and symptoms of TB and the action to be taken if these occur, to be cascaded to staff via the Ward Manager, Matron and the TB Team

Any required follow-up of contacts (including provision of "Inform and Advise" information) will be done via the CHFT Chest Clinic.



**UNIQUE IDENTIFIER NO: C-67-2013**

**EQUIP-2017-074**

**Review Date: July 2020**

**Review Lead: Lead Infection Prevention & Control Nurse**

## **10. Training and Implementation**

IPC precautions required when caring for all patients is included in the 'Right from the Start' mandatory training sessions which are to be attended by all staff commencing employment with CHFT who will work in a clinical area. The IPCT also delivers targeted training sessions to key personnel / areas including Link Infection Prevention and Control Practitioners in departments and wards across the Trust who will then cascade the information to appropriate colleagues within their area / departments.

## **11. Trust Equalities Statement**

Calderdale and Huddersfield NHS Foundation Trust aims to design and implement services, policies and measures that meet the diverse needs of our service, population and workforce, ensuring that none are placed at a disadvantage over others. We therefore aim to ensure that in both employment and services no individual is discriminated against by reason of their gender, gender reassignment, race, disability, age, sexual orientation, religion or religious/philosophical belief, marital status or civil partnerships.

This policy has been through the Trust's EQUIP (Equality Impact Assessment Process) to assess the effects that it is likely to have on people from different protected groups, as defined in the Equality Act 2010.

## **12. Process for Monitoring Compliance/Effectiveness**

If a patient cannot be isolated appropriately, this must be reported in Datix by the clinical staff and communicated to the IPCT.

Records of non-availability of single rooms compliance is monitored by the Divisions.

Incidents and outbreaks are monitored by the Infection Prevention and Control Team and where there is staff involvement by the Occupational Health Service and reported via the Infection Control Committee.

## **13. References and Further Reading**

PHE (2016) Tuberculosis in England 2016 report (presenting data to the end of 2015)

CDC. Notice to readers: revised definition of extensively drug-resistant tuberculosis. *MMWR* 2006; 55:1176.

**UNIQUE IDENTIFIER NO: C-67-2013**

**EQUIP-2017-074**

**Review Date: July 2020**

**Review Lead: Lead Infection Prevention & Control Nurse**

Collaborative Tuberculosis Strategy for England 2015-2020. Public Health England, NHS England. London. 2015. The Collaborative Tuberculosis Strategy for England 2015-2020 can be accessed via the link:

<https://www.gov.uk/government/publications/collaborative-tuberculosis-strategy-for-england>

Health and Safety Executive. A guide to the Reporting of Injuries, Disease and Dangerous Occurrences Regulations 1995. HSE Reprinted with amendments 2009.

Public Health England TB Strategy Monitoring Indicators Tool:

<http://fingertips.phe.org.uk/profile/tb-monitoring>

NICE (2016) Tuberculosis: [NICE guideline](#).

Ventilation in Healthcare Premises: Please follow the link below for more information about ventilation in healthcare premises HTM 03-01

[https://www.gov.uk/government/uploads/system/uploads/attachment\\_data/file/144029/HTM\\_03-01\\_Part\\_A.pdf](https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/144029/HTM_03-01_Part_A.pdf)

UNIQUE IDENTIFIER NO: C-67-2013

EQUIP-2017-074

Review Date: July 2020

Review Lead: Lead Infection Prevention & Control Nurse



## APPENDIX 1

### Guidance on notifying Tuberculosis (TB) cases

<b>Statutory notification of Tuberculosis (TB)</b>	All forms of active TB are statutorily notifiable <sup>1</sup> . The notification of cases prompts timely risk assessment for appropriate clinical and public health responses to cases and their contacts. The information provided through notification is used for epidemiological surveillance to control TB and to identify cases for cohort review.
<b>What to notify</b>	All new tuberculosis cases that meet one of the two following case definitions Culture confirmed case due to <i>M. tuberculosis</i> complex (including <i>M. tuberculosis</i> , <i>M. bovis</i> , <i>M. africanum</i> or <i>M. microti</i> ). In the absence of culture confirmation, a case that meets the following criteria: <ul style="list-style-type: none"><li>a clinician's judgement that the patient's clinical and/or radiological signs and/or symptoms are compatible with tuberculosis,</li></ul> AND <ul style="list-style-type: none"><li>a clinician's decision to treat the patient with a full course of anti-TB therapy.</li></ul> The requirement to notify applies if there is reasonable ground for suspecting that a patient has died with, but not necessarily from, active TB (including post mortem diagnoses) Notification requirement applies also to UK residents who are diagnosed abroad but continue with their anti-TB therapy in the UK and to non-UK residents diagnosed in the UK, even if anti-TB therapy is not initiated in the UK
<b>What NOT to notify</b>	<ul style="list-style-type: none"><li>mycobacterium cases not belonging to the <i>M. tuberculosis</i> complex</li><li>latent TB infection cases receiving anti TB chemoprophylaxis</li><li>cases with disseminated disease resulting from BCG</li></ul>
<b>Mechanism for notification</b>	Statutory notification for TB cases is made through the Enhanced TB Surveillance system (ETS) (or the London TB Register, LTBR, in London). Both systems are accessible online for timely notification. For those without online access, paper forms exist and can be requested from the local PHE Health Protection Team.
<b>When to notify</b>	<ul style="list-style-type: none"><li>TB cases should be notified within 3 working days of making or suspecting the diagnosis</li><li>notification should not be delayed if full case information (including laboratory confirmation) is not available, as additional information can be added later</li><li>a case can be subsequently de-notified if an alternative diagnosis or contamination is confirmed</li><li>if a case requires immediate public health action, the local PHE Health Protection Team should be contacted as soon as possible, and always within 24 hours</li><li>any urgent verbal notification must be followed up through ETS/LTBR</li></ul>
<b>Roles &amp; responsibilities</b>	<b>Registered Medical Practitioner (RMP)</b> There is a legal requirement for NHS & private sector Registered Medical Practitioners (RMPs) to notify, where they suspect a case of TB. <b>Specialist Nurses</b> TB/respiratory/infectious disease specialist nurses should liaise with the appropriate RMP to ensure that cases are notified in a timely manner.
<b>Mechanisms to improve notification</b>	<ul style="list-style-type: none"><li>move from paper-based to electronic notification through ETS/LTBR</li><li>local agreement for designated nurses to notify cases on behalf of the RMP</li><li>microbiologists / pathologists to inform the local TB team of positive results received from non-TB specialists to ensure notification occurs</li></ul>

PHE publications gateway number: 2014370 © Crown copyright 2014

1. Health Protection Legislation (England) Guidance 2010:

[http://webarchive.nationalarchives.gov.uk/20130107105354/http://www.dh.gov.uk/prod\\_consum\\_dh/groups/dh\\_digitalassets/@dh/@en/@ps/documents/digitalasset/dh\\_114589.pdf](http://webarchive.nationalarchives.gov.uk/20130107105354/http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/@ps/documents/digitalasset/dh_114589.pdf)

**For queries relating to this guidance, please contact: [tbsection@phe.gov.uk](mailto:tbsection@phe.gov.uk)**

UNIQUE IDENTIFIER NO: C-67-2013

EQUIP-2017-074

Review Date: July 2020

Review Lead: Lead Infection Prevention & Control Nurse

APPENDIX 2

### Pressure Room Availability at CRH

Ward 1 - 1D – Room G-074 SR 4 available

Ward 2 - 2C – Room 1-073 unavailable as used as an assessment room

2D – Room 1-072 available

Ward 3 3C – Room 005 No pressure gauge outside the side room

Ward 4 - 4C – Room 3-071, 3-075 unavailable as both used as examination rooms

4D – Room 3-094 currently open as medical otherwise unavailable

Ward 5 - 5C – Rooms G-068, G-054, G-072, G-058 all available

5D – Rooms G-073, G-069 both unavailable as the ward is closed

Ward 6 - 6C – Room 1-074 SR 4 available

6D – Room 1-075 SR 1 unavailable as the ward is closed

Ward 7 - 7C – Room 2-072 SR 1 available

7D – Room 2-073 SR 4 available

Ward 8 - 8C – Room 3-074 SR 4 available

8D – Room 3-073 SR 1 available

SCBU - Rooms 015, 016 available if required

ICU/HDU - Rooms 006, 013, 015, 025 only 2 pressure rooms available

CCU - Room CC-013 SR 1 available

### **PROCEDURE FOR CHANGE FROM NEGATIVE TO POSITIVE PRESSURE (NB. All pressure rooms are set centrally to negative pressure)**

#### **MONDAY - FRIDAY 8am - 5pm**

- Clinical Lead to contact Infection Control Nurse with request
- Infection Control Nurse to contact Engie Help Desk on Ext: 4634 to request change in pressure AND complete form for switch to take place
- Engie personnel to complete form
- Switch to be completed and checks made to ensure pressure change

#### **Out of hours (MONDAY - FRIDAY 5pm - 8am and WEEKENDS/BHs)**

- Clinical Lead to contact ISS Duty Manager
- ISS Duty Manager to contact Infection Control Nurse on Call
- ISS Duty Manager to commence completion of form for switch to take place
- Infection Control Nurse to authorise Matron on Call or Site Co-Ordinator to sign form
- ISS Duty Manager to contact Engie on Call
- Engie on Call to complete form
- Switch to be completed and checks made to ensure pressure change

**NB: please ensure that a form is completed for the return of a room to negative pressure when positive pressure is no longer required e.g. on discharge of patient or transfer to another area.**

**All forms to be retained in file at main reception.**

UNIQUE IDENTIFIER NO: C-67-2013  
EQUIP-2017-074  
Review Date: July 2020  
Review Lead: Lead Infection Prevention & Control Nurse

## SWITCH +/- PRESSURE

Room Number: ..... Ward: .....

Date: .....

Requested By (Clinical Lead) Name: .....

Title: .....

Authorised By Infection Control Nurse (Mon – Fri 8am - 5pm)  
Or Duty Matron or Site Co-ordinator (5pm - 8am Mon – Fri and Weekends)

Name: ..... Signature: .....

Title: .....

Tick Relevant Box

Switch from + to -

Switch from - to +

Concept Task Number .....


Carried out by

Name: ..... Signature: .....

Date: ..... Time: .....

Confirmation of Pressure status .....

**Assessment of Isolation Requirements (applies to pulmonary TB only).  
(as per NICE Guidelines March 2011)**



## Guide for risk assessment of TB exposure incidents in hospitals

*Produced in Yorkshire & The Humber by a joint HPA and NHS Working Group, Final draft, September 2012*

### Introduction

#### Who is this for?

This guide is intended for anyone involved in the risk assessment and management of TB exposure incidents in a hospital setting.

#### Background

Healthcare settings are the most common environment for non-household TB exposure incidents. A recent retrospective review of TB incidents in schools, prisons and hospital settings in 2010 found that out of these three settings, most incidents occurred in hospital settings<sup>1</sup>. However, the yield of positives per 100 people screened was significantly lower in the hospital setting compared to the other settings suggesting that there may be inconsistencies with contact screening. Also anecdotal evidence from the Yorkshire and Humber region suggested that there were instances of a lack of clarity in decision making. As a result this tool was developed by West Yorkshire Health Protection Unit to help improve the management of TB exposure incidents in hospital. TB exposure incidents are any incidents where a potential for TB transmission is identified within hospital setting which may necessitate public health action.

This tool was developed based on a literature review, current best practice guidance and feedback from experts in the field of TB from the Health Protection Agency, nationally, and the Yorkshire and Humber TB professionals network. The literature review focussed on the risk and risk factors associated with hospital TB exposure incidents in high resource, low TB burden countries. Research in this area is sparse, and there is a distinct lack of good quality epidemiological studies, probably due to the fact it is a relatively rare event which makes cohort studies impractical and case control studies difficult due to identifying an appropriate control group. It is also difficult to measure the precise impact of individual and environmental control measures as many were introduced simultaneously. Most of the literature on nosocomial transmission in low incidence settings is based on the risk of patient-to-healthcare worker transmission and not patient-to-patient transmission. In fact, this literature review only identified one systematic review of the risk factors associated with TB exposure incidents and this was based on a neonatal population<sup>2</sup>.

The tool focuses on the factors that are associated with transmission namely: the infectiousness of the case, duration of exposure and characteristics of those exposed to the case. These factors are the same whatever the setting, but what makes the hospital setting distinct from a community setting are: the potential for a concentration of susceptible patients; the exposure opportunities posed by certain types of procedures and the opportunities for unwittingly sharing a closed environment (ward) with an infectious case of TB.


#### NICE guidance: Contact tracing: cases in hospital inpatients<sup>3</sup>

- Following diagnosis of TB in a hospital inpatient, a risk assessment should be undertaken. This should take into account:
  - of the degree of infectivity of the index case;
  - the length of time before the infectious patient was isolated;
  - whether other patients are unusually susceptible to infection
  - the proximity of contact.
- Contact tracing and testing should be carried out only for patients for whom the risk is regarded as significant.
- Patients should be regarded as at risk of infection if they spent more than 8 hours in the same bay as an inpatient with sputum smear-positive TB who had a cough. The risk should be documented in the contact's clinical notes, for the attention of the contact's consultant. The contact should be given 'inform and advise' information, and their GP should be informed.
- If patients were exposed to a patient with sputum smear-positive TB for long enough to be equivalent to household contacts (as determined by the risk assessment), OR an exposed patient is known to be particularly susceptible to infection, they should be managed as equivalent to household contacts.
- If an inpatient with sputum smear-positive TB is found to have MDR TB, or if exposed patients are HIV-positive, contact tracing should be in line with The Interdepartmental Working Group on Tuberculosis guidelines<sup>4</sup>.
- In cases of doubt when planning contact tracing after diagnosing sputum smear-positive TB in an inpatient, further advice should be sought from the regional or national Health Protection Agency and/or people experienced in the field.

**Disclaimer:** This tool is still in development. It is intended to be used to assist the risk assessment process for a hospital TB exposure incident. However there may be some complicated circumstances of TB exposure in a hospital setting where use of this tool may not be appropriate.

**Feedback:** Developing the guide has been an iterative process. It is still a working document and comments would be gratefully received. Please direct comments to Dr Ebere Okereke, TB lead Yorkshire & Humber Region: [ebere.okereke@hpa.org.uk](mailto:ebere.okereke@hpa.org.uk)

Guide



**UNIQUE IDENTIFIER NO: C-67-2013**

**EQUIP-2017-074**

**Review Date: July 2020**

**Review Lead: Lead Infection Prevention & Control Nurse**

Action	
1	a) <b>Consider</b> inform and advice to vulnerable (in groups 1 <sup>vi</sup> and 2 <sup>vii</sup> ), close contacts on the ward.
2	a) Inform and advice only to all patients and staff on the ward. b) <b>Consider</b> screening any vulnerable contacts in group 1 <sup>vi</sup> on the ward. c) <b>Consider</b> screening HCWs involved in aerosol generating procedures without appropriate PPE.
3	a) Screen all patients for whom the HCW is named HCW and for whom he/she provided close clinical care <sup>viii</sup> . b) <b>Consider</b> screening for vulnerable patients in groups 1 <sup>vi</sup> and 2 <sup>vii</sup> on the ward where index case worked. c) Screen staff who are regularly on the same shifts with index case. d) Inform and advice to rest of staff on the ward. e) Inform and advice to patients who have been on the ward for more than 8 hours cumulatively where index case worked.
4	a) <b>Consider</b> screening vulnerable contacts. b) Inform and advice to patients in closest 2 beds on either side of the index case and staff. c) Screen staff involved in aerosol generating procedures without appropriate PPE.
5	a) Screen all patients in closest 2 beds on either side of the index case. b) <b>Consider</b> screening all vulnerable contacts in groups 1 <sup>vi</sup> and 2 <sup>vii</sup> on the ward. c) Screen staff involved in close clinical care <sup>viii</sup> of index case. d) Inform and advice to rest of staff and patients on the ward.
6	a) <b>Consider</b> screening vulnerable contacts in groups 1 <sup>vi</sup> and 2 <sup>vii</sup> . b) Inform and advice to patients in unit / bay and staff. c) Screen staff involved in aerosol generating procedures without appropriate PPE.
7	a) Screen all patients and contacts in the unit / bay. b) Screen staff involved in close clinical care <sup>viii</sup> of index case. c) Inform and advice to rest of staff on the unit.
8	a) <b>Consider</b> screening vulnerable contacts in groups 1 <sup>vi</sup> and 2 <sup>vii</sup> who regularly attended the same outpatient clinic on same dates as index case. b) Inform and advice to patients who regularly attended the same outpatient clinic at same dates as index case and staff. c) Screen staff involved in aerosol generating procedures without appropriate PPE.
9	a) Screen all vulnerable contacts in groups 1 <sup>vi</sup> and 2 <sup>vii</sup> who regularly attended the same outpatient clinic on the same dates and times as the index case. b) Inform and advice to other patients who attended the same outpatient clinic on the same dates and times as index case. c) Screen staff involved in repeated close prolonged care of index case or involved in aerosol generating procedures without appropriate PPE. d) Inform and advice to rest of the staff

**Consider – discretionary based on local circumstances**

**Footnotes**

<sup>i</sup> Effective TB treatment: Standard 4 drug regime where disease is known to be fully sensitive disease from standard culture-based drug sensitively testing or PCR-based tests or where there is no reason to suspect drug-resistant disease AND patient adherence to treatment is not in doubt. In the case of MDR/XDR TB, 3 x smear negative sputum samples are required to establish effectiveness of treatment.

<sup>ii</sup> Adequate isolation: en-suite single occupancy room or negative pressure room for MDR TB and appropriate PPE for any staff procedures for the duration of the infectious period

<sup>iii</sup> Duration of exposure refers to cumulative exposure over one week period. For identifying contacts, consider the infectious period for the index case – onset of symptoms for symptomatic index case or 4 weeks prior to diagnosis for asymptomatic index case.<sup>3</sup>

<sup>iv</sup> Small unit: Include ICU/HDU/NICU/ renal dialysis unit, ward bay with 8 or less beds. If patients in ICU-type setting are on closed ventilation system, screening may not be required

<sup>v</sup> In outpatient settings, it is unlikely that patients attending outpatient clinics would achieve up to 8 hours cumulative exposure except in day units such as day case surgery units, dialysis and other outpatient treatment units such as might be used for transfusions and chemotherapy.

<sup>vi</sup> Group 1: High risk individuals in any of these groups:

- HIV positive
- Child aged 5 year or under (including neonates)
- Injecting drug users and alcohol misusers
- Recipient of solid organ transplant
- Receiving anti-tumour necrosis factor(TNF) - alpha treatment
- Jejunioileal bypass
- Haematological malignancy
- On high corticosteroid therapy (>15mg of prednisolone or equivalents/day for >2-4 weeks)
- Other immunosuppressive treatment such as chemotherapy for cancer or transplants
- Silicosis

<sup>vii</sup> Group 2: Medium risk individuals in any of these groups:

- Chronic renal failure or receiving haemodialysis,
- Gastrectomy
- Diabetes Mellitus
- Head and neck cancer
- Significantly underweight
- Radiographic findings consistent with prior TB
- Chronic malabsorption syndrome

<sup>viii</sup> Close nursing care involving regular or prolonged close contact within 3 feet/ 1 metre of the patient or staff who are involved in aerosol producing procedures without appropriate PPE.

<sup>ix</sup> In exceptional circumstances where microbiological confirmation is not possible, if an experienced TB specialist is satisfied that the diagnosis is TB, for purposes of risk assessment, treat as if microbiologically confirmed TB.

**UNIQUE IDENTIFIER NO: C-67-2013**  
**EQUIP-2017-074**  
**Review Date: July 2020**  
**Review Lead: Lead Infection Prevention & Control Nurse**

**APPENDIX 5**

**Patients Who Have Come into Contact with Index Case**

**Index case- Initials and Unit Number.....**  
**Ward/Department.....**  
**Admission Date.....**  
**Discharge Date.....**

<b>Patients Name</b>	<b>Date of Admission</b>	<b>Patients Address</b>	<b>Unit Number</b>	<b>DOB</b>	<b>Consultant</b>	<b>Date of Discharge</b>	<b>Discharged To</b>

**UNIQUE IDENTIFIER NO: C-67-2013**  
**EQUIP-2017-074**  
**Review Date: July 2020**  
**Review Lead: Lead Infection Prevention & Control Nurse**

**Staff Who Have Come into Contact with Index Case**

**Index case- Initials and Unit Number.....**  
**Ward/Department.....**  
**Admission Date.....**  
**Discharge Date.....**

Staff member name/DOB	Date of Contact	Nature of exposure	PPE worn	

